Eris Lifesciences Limited (NSE:ERIS)
India
· Delayed Price · Currency is INR 1,675.80
+57.80 (3.57%)
Jun 27, 2025, 3:30 PM IST
Eris Lifesciences Revenue
In the fiscal year ending March 31, 2025, Eris Lifesciences had annual revenue of 28.79B INR with 44.59% growth. Eris Lifesciences had revenue of 7.03B in the quarter ending March 31, 2025, with 28.38% growth.
Revenue
28.79B
Revenue Growth
+44.59%
P/S Ratio
8.42
Revenue / Employee
7.95M
Employees
3,620
Market Cap
242.46B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 28.79B | 8.88B | 44.59% |
| Mar 31, 2024 | 19.91B | 3.29B | 19.83% |
| Mar 31, 2023 | 16.62B | 3.36B | 25.31% |
| Mar 31, 2022 | 13.26B | 1.34B | 11.20% |
| Mar 31, 2021 | 11.93B | 1.34B | 12.71% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 525.78B |
| Divi's Laboratories | 93.60B |
| Cipla | 272.67B |
| Apollo Hospitals Enterprise | 217.94B |
| Zydus Lifesciences | 232.42B |
| Mankind Pharma | 122.07B |
| Aurobindo Pharma | 317.24B |
| Fortis Healthcare | 77.83B |
Eris Lifesciences News
- 5 weeks ago - Eris Lifesciences shares jump 3% as Q4 EBITDA rises 69.8% YoY to 252.2 crore - Business Upturn
- 2 months ago - Eris Lifesciences, Lupin and Biocon shares in focus as Novo Nordisk exits Rs 800 crore Human Mixtard brand, says report - Business Upturn
- 2 months ago - Eris Lifesciences shares surge over 4% as Novo Nordisk reportedly exits Human Mixtard insulin market in India - Business Upturn
- 5 months ago - Eris Lifesciences shares drop 4% as net profit dips 14.3% YoY in Q3 - Business Upturn
- 5 months ago - Eris Lifesciences Q3 FY25 Results: Revenue up 49.6% YoY to Rs 727.45 crore, Net profit dips 14.3% - Business Upturn
- 8 months ago - Eris Lifesciences Q2 results: Revenue rises 46.7% YoY to ₹741.17 crore, Net Profit falls 21.2% YoY - Business Upturn
- 9 months ago - Market movers: BSE rises 6.90%, JP Power up 4.96%, JSW Steel gains 1.98%, Jindal Steel climbs 2.43%, Eris Lifesciences up 3.56%, Just Dial adds 2.53% among key gainers - Business Upturn
- 9 months ago - Eris Lifesciences stock up 3.24%, sees ₹270.76 crore block deal as 2 million shares change hands - Business Upturn